Estrogen for Alzheimer’s disease in women
暂无分享,去创建一个
B L Miller | R. Elble | V. Henderson | A. Hake | A. Paganini-Hill | B. Miller | R. Elble | D. Shoupe | M R Farlow | V W Henderson | Carol A. McCleary | A Paganini-Hill | P. Reyes | D Shoupe | R J Elble | C. McCleary | R. Klein | M. Farlow | P F Reyes | C A McCleary | R A Klein | A M Hake | M. Farlow | Bruce L. Miller | B. Miller
[1] J. Buckwalter,et al. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. , 1994, Archives of neurology.
[2] C. Pike,et al. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease. , 2001, Journal of neurochemistry.
[3] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[4] L. Schneider,et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease , 1996, Neurology.
[5] Y. Agid,et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .
[6] S. Birge. The role of estrogen in the treatment of Alzheimer's disease , 1997, Neurology.
[7] H. Fillit. Estrogens in the Pathogenesis and Treatment of Alzheimer's Disease in Postmenopausal Women , 1994, Annals of the New York Academy of Sciences.
[8] R. Katzman.,et al. Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.
[9] J. Studd,et al. Exogenous androgens in postmenopausal women. , 1995, The American journal of medicine.
[10] D. Evans,et al. Estimated prevalence of Alzheimer's disease in the United States. , 1990, The Milbank quarterly.
[11] B. Sherwin,et al. Effects of estrogen on memory function in surgically menopausal women , 1992, Psychoneuroendocrinology.
[12] D. Mishell,et al. Comparison of pharmacodynamic properties of various estrogen formulations. , 1982, American journal of obstetrics and gynecology.
[13] N. Hagino,et al. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. , 1995, Dementia.
[14] W. Jusko,et al. Differences in pharmacokinetics and comparative bioavailability between premarin® and estratab® in healthy postmenopausal women , 1994 .
[15] "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. , 1997, The Journal of clinical endocrinology and metabolism.
[16] L. Freedman,et al. Allocation of patients to treatment groups in a controlled clinical study. , 1978, British Journal of Cancer.
[17] R. L. Moss,et al. Nongenomic actions of estrogen in the brain: physiological significance and cellular mechanisms. , 1996, Critical reviews in neurobiology.
[18] M. Lawton,et al. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .
[19] Yaakov Stern,et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.
[20] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[21] P Dal-Bianco,et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.
[22] P. Shughrue,et al. Comparative distribution of estrogen receptor‐α and ‐β mRNA in the rat central nervous system , 1997, The Journal of comparative neurology.
[23] K. Davis,et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. , 1988, Psychopharmacology bulletin.
[24] V. Henderson,et al. Estrogen replacement therapy and risk of Alzheimer disease. , 1996, Archives of internal medicine.
[25] G. Chazot,et al. The Physiology and Pharmacology of Melatonin in Humans , 1998, Hormone Research in Paediatrics.
[26] V. Henderson. Estrogen Replacement Therapy for the Prevention and Treatment of Alzheimer’s Disease , 1997 .
[27] R. Brookmeyer,et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.
[28] S. Asthana,et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer’s disease: results of a placebo-controlled, double-blind, pilot study , 1999, Psychoneuroendocrinology.
[29] M. Lawton,et al. Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.
[30] J. Galen Buckwalter,et al. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease , 1996, Psychoneuroendocrinology.
[31] Gastone G. Celesia,et al. A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .
[32] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[33] K. Davis,et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.
[34] D. Singer,et al. Determinants of compliance with anticoagulation: A case-control study. , 1997, The American journal of medicine.
[35] P. Greengard,et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides , 1998, Nature Medicine.
[36] R Brookmeyer,et al. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.
[37] E G Tangalos,et al. Postmenopausal estrogen replacement therapy and risk of AD , 1999, Neurology.
[38] V. Henderson. Estrogen, cognition, and a woman's risk of Alzheimer's disease. , 1997, The American journal of medicine.
[39] L. Amaducci,et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging , 1998, Neurology.
[40] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[41] T. Morgan,et al. Increased Synaptic Sprouting in Response to Estrogen via an Apolipoprotein E-Dependent Mechanism: Implications for Alzheimer’s Disease , 1998, The Journal of Neuroscience.
[42] M. Lezak. Neuropsychological assessment, 3rd ed. , 1995 .